Mike Ufer

List of Publications by Year
in descending order

28 papers	1,157 citations	430874 18 h-index	501196 28 g-index
28 all docs	28 docs citations	28 times ranked	1330 citing authors

#	Article	IF	Citations
1	Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep, 2022, 45, .	1.1	23
2	Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects. Clinical Pharmacokinetics, 2022, 61, 687-695.	3.5	2
3	Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. Thrombosis and Haemostasis, 2021, 121, 755-766.	3.4	9
4	Effect of the novel dual orexin receptor antagonist daridorexant on nightâ€time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. Journal of Sleep Research, 2021, 30, e13248.	3.2	15
5	Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep, 2021, 44, .	1.1	22
6	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal, 2020, 41, 3132-3140.	2.2	52
7	Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists. Clinical Pharmacokinetics, 2020, 59, 545-566.	3.5	44
8	Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2020, 75, 2588-2597.	2.8	53
9	Clinical Pharmacology of the Reversible and Potent P2Y₁₂ Receptor Antagonist ACTâ€246475 After Single Subcutaneous Administration in Healthy Male Subjects. Journal of Clinical Pharmacology, 2019, 59, 123-130.	2.0	27
10	The selective metabotropic glutamate receptor 5 antagonist mavoglurant (<scp>AFQ</scp>056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease. Neurogastroenterology and Motility, 2017, 29, e13058.	3.0	10
11	Metabolism and Disposition of the Metabotropic Glutamate Receptor 5 Antagonist (mGluR5) Mavoglurant (AFQ056) in Healthy Subjects. Drug Metabolism and Disposition, 2013, 41, 1626-1641.	3.3	23
12	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thrombosis and Haemostasis, 2010, 103, 572-585.	3.4	119
13	Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics, 2009, 10, 1941-1953.	1.3	44
14	Influence of CYP3A4, CYP3A5, and ABCB1 Genotype and Expression on Budesonide Pharmacokinetics: A Possible Role of Intestinal CYP3A4 Expression. Clinical Pharmacology and Therapeutics, 2008, 84, 43-46.	4.7	29
15	Effects of polymorphisms on phenprocoumon anticoagulation status. Clinical Pharmacology and Therapeutics, 2005, 77, 335-336.	4.7	5
16	Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes. Analytical and Bioanalytical Chemistry, 2005, 383, 909-917.	3.7	12
17	Achiralâ€“chiral LC/LCâ€“MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism. Analytical Biochemistry, 2005, 339, 297-309.	2.4	17
18	Antimicrobial drug use in hospitalised paediatric patients: a cross-national comparison between Germany and Croatia. Pharmacoepidemiology and Drug Safety, 2005, 14, 735-739.	1.9	19

#	Article	IF	Citations
19	Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiology and Drug Safety, 2005, 14, 493-499.	1.9	54
20	Comparative Pharmacokinetics of Vitamin K Antagonists. Clinical Pharmacokinetics, 2005, 44, 1227-1246.	3.5	248
21	Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylationin vitroandin vivo. Xenobiotica, 2004, 34, 847-859.	1.1	28
22	Identification of cytochromes P 450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. European Journal of Clinical Pharmacology, 2004, 60, 173-182.	1.9	69
23	Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiology and Drug Safety, 2004, 13, 147-152.	1.9	65
24	Determination of(R)- and(S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2004, 18, 458-464.	1.5	13
25	Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatographyâ€“mass spectrometry after solid-phase extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 809, 217-226.	2.3	34
26	Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics and Genomics, 2004, 14, 19-26.	5.7	80
27	Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. European Journal of Clinical Pharmacology, 2003, 58, 779-783.	1.9	40
28	Off-label paediatric prescribing in Stockholm (Sweden): a response to a letter to the editor. European Journal of Clinical Pharmacology, 2003, 59, 493-494.	1.9	1